Biomarkers in the monitoring of anticoagulant therapies: Clinical applications, diagnostic efficacy, and challenges for the clinical laboratory. Literature review.
DOI:
https://doi.org/10.56294/saludcyt20251978Keywords:
Biomarkers, Anticoagulants, Monitoring, Anticoagulant therapyAbstract
The implementation of coagulation assays enables precise evaluation of the hemostatic status of patients, which is essential for the prevention of thrombotic events such as deep vein thrombosis, pulmonary embolism, cerebrovascular accidents, and acute myocardial infarction.
We conducted a literature review following the PRISMA guidelines, encompassing 78 articles published between 2019 and 2025 that focused on biomarkers for monitoring anticoagulant therapy. Of these, 38 studies met eligibility criteria by providing data on sensitivity, specificity, advantages and limitations of the biomarkers in anticoagulants patients.
Results demonstrated that traditional biomarkers, including platelet count, prothrombin time, international normalized ratio, activated partial thromboplastin time, D dimer, are useful for evaluating coagulation activation but have notable limitations in patients treated with direct anticoagulants. In contrast, advanced assays, such as thrombin generation assays, allow comprehensive analysis of the entire thrombin generation process, offering a more complete assessment of the hemostatic system. The combined use of conventional biomarkers and global assays holds significant potential to markedly improve anticoagulant therapy monitoring by facilitating safe individualization of treatment and minimizing both thrombotic and hemorrhagic risk.
References
1. González-Villalva A, de la Peña-Díaz A, Rojas-Lemus M, López-Valdez N, Ustarroz-Cano M, García-Peláez I, et al. Fisiología de la hemostasia y su alteración por la coagulopatía en COVID-19. Revista de la Facultad de Medicina. 2020 Sep 25;63(5):45–57.
2. Vera O. Basic and clinical pharmacology of anticoagulants. Scielo [Internet]. 2022 [cited January 24, 2025]; 63(1): 55–63. Available from: http://www.scielo.org.bo/scielo.php?script=sci_arttext&pid=S1652-67762022000100009
3. Vallejos A, Bello A, Domínguez M, Cuervo M, Fajardo D, Quiroga C, et al. Profile of anticoagulant use in hospitalized patients, drug interactions, and identified adverse reactions. Scielo [Internet]. 2020 [cited January 24, 2025]; 49(1): 137–158. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0034-74182020000100137
4. Perifanis V, Neokleous N, Tsakiris DA. Update on laboratory testing and hemostasis assessment in patients receiving direct oral anticoagulants (DOACs). ScienceDirect [Internet]. 2021 [cited January 24, 2025]; 5:100084–4. Available at: https://www.sciencedirect.com/science/article/pii/S2666572721000535
5. Ou FS, Michiels S, Shyr Y, Adjei AA, Oberg AL. Biomarker Discovery and Validation: Statistical Considerations. ScienceDirect [Internet]. 2021 [cited 2025 January 24]; 16(4): 537–45. Available from: https://www.sciencedirect.com/science/article/pii/S1556086421016634
6. Nabila N, Iberahim S, Mohd N, Zulkafli Z, Muzaffar T, Din MH, et al. Haemostasis and Inflammatory Parameters as Potential Diagnostic Biomarkers for VTE in Trauma-Immobilized Patients. PubMed Central [Internet]. 2023 [cited January 24, 2025]; 13(1): 150–0. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9818770/
7. Ballestri S, Romagnoli E, Arioli D, Coluccio V, Marrazzo A, Athanasiou A, et al. Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review. PubMed Central [Internet]. 2022 [cited January 24, 2025]; 40(1): 41–66. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9569921/
8. Gauer RL WDJ. thrombocytopenia. [cited 2025 Aug 9]; Available from: https://pubmed.ncbi.nlm.nih.gov/36126009/
9. Di Micco P, Monreal M. Platelet count and bleeding in patients receiving anticoagulant therapy for venous thromboembolism: Lesson from the RIETE registry [Internet]. Vol. 10, Journal of Blood Medicine. Dove Medical Press Ltd; 2019 [cited 2025 Aug 9]. p. 453–6. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6997195/pdf/jbm-10-453.pdf
10. Marin MJ, Harris N, Winter W, Zumberg MS. A Rational Approach to Coagulation Testing. Laboratory Medicine [Internet]. 2022 [cited December 31, 2024]; 53(4): 349–59. Available from: https://doi.org/10.1093/labmed/lmac005
11. Winter WE, Flax SD, Harris NS. Coagulation Testing in the Core Laboratory. Laboratory Medicine [Internet]. 2017 [cited December 31, 2024]; 48(4): 295–313. Available from: https://pubmed.ncbi.nlm.nih.gov/29126301/
12. Ayuso Murillo D, Fontán Vinagre G, Enríquez Jiménez M, Jesús Musarra Expósito M, Soler Pardo E, Práctica Centrada En La Enfermedad A La Atención Centrada En El Paciente D LA, et al. DIRECCIÓN DEL PROYECTO GUÍA DE RECOMENDACIONES PRÁCTICAS en [Internet]. 2023. Available from: www.consejogeneralenfermeria.org
13. Wermine K, Song J, Gotewal S, Huang L, Corona K, Bagby S, et al. The Utilisation of INR to identify coagulopathy in burn patients. PLoS One. 2024 Feb 1;19(2 February).
14. Wang HX, Han B, Zhao YY, Kou L, Guo LL, Sun TW, et al. Serum D-dimer as a potential new biomarker for prognosis in patients with thrombotic thrombocytopenic purpura. Medicine [Internet]. 2020 [cited 2024-12-31]; 99(13): e19563. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7220495/
15. Morales M, Agramonte M, Tamayo Y. Diagnostic utility of quantitative D-dimer. Scielo [Internet]. 2020 [cited December 31, 2024]; 36(4): Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892020000400004
16. Ahmad U, Frederiksen JL. Fibrinogen: A potential biomarker for predicting disease severity in multiple sclerosis. ScienceDirect [Internet]. 2020 [cited 31 December 2024]; 46: 102509–9. Available from: https://www.sciencedirect.com/science/article/abs/pii/S2211034820305848
17. Cohen H, Efthymiou M, Katrien M.J. Monitoring of anticoagulation in thrombotic antiphospholipid syndrome. ScienceDirect [Internet]. 2020 [cited 2024-12-31]; 19(4): 892–908. Available at: https://www.sciencedirect.com/science/article/pii/S1538783622007103
18. Depasse F, Binder NB, Mueller J, Wissel T, Schwers S, Germer M, et al. Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine. Pubmed Central [Internet]. 2021 [cited January 11, 2025]; 19(12): 2907–17. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9291770/
19. Binder NB, Depasse F, Mueller J, Wissel T, Schwers S, Germer M, et al. Clinical use of thrombin generation assays. Pubmed [Internet]. 2021 [cited 11 January 2025]; 19(12): 2918–29. Available from: https://pubmed.ncbi.nlm.nih.gov/34592058/
20. Sidonio RF, Hoffman M, Dargaud Y. Thrombin generation and implications for hemophilia therapies: A narrative review. ELSERVIER [Internet]. 2023 [cited January 11, 2025]; 7(1): 100018–8. Available from: https://www.sciencedirect.com/science/article/pii/S2475037922022683
21. Mackie I, Casini A, Pieters M, Rajiv Pruthi, Reilly‐Stitt C, Suzuki A. International council for standardization in haematology recommendations on fibrinogen assays, thrombin clotting time and related tests in the investigation of bleeding disorders. International Journal of Laboratory Hematology [Internet]. 2023 [cited 2024 Dec 31];46(1): 20–32. Available at: https://onlinelibrary.wiley.com/doi/10.1111/ijlh.14201
22. Binder NB, Depasse F, Mueller J, Wissel T, Schwers S, Germer M, et al. Clinical use of thrombin generation assays. Journal of Thrombosis and Haemostasis [Internet]. 2021 [cited 2024-12-31]; 19(12): 2918–29. Available at: https://www.jthjournal.org/article/S1538-7836(22)00556-6/fulltext
23. Batsuli G, Kouides P. Rare Coagulation Factor Deficiencies (Factors VII, X, V, and II). Hematology/Oncology Clinics of North America [Internet]. 2021 [cited January 11, 2025]; 35(6): 1181–96. Available at: https://www.hemonc.theclinics.com/article/S0889-8588(21)00089-7/fulltext
24. Peyvandi F, Auerswald G, Austin SK, Liesner R, Kavakli K, Teresa M, et al. Diagnosis, therapeutic advances, and key recommendations for the management of factor ELSEVIER [Internet]. 2021 [cited January 11, 2025]; 50:100833–3. Available at: https://www.sciencedirect.com/science/article/pii/S0268960X21000394
25. Greenmyer JR, Niaz T, Kohorst MA, Stephens EH, Anderson JH. Chromogenic Factor X Assay for Monitoring Warfarin Anticoagulation in a Child With a Prosthetic Mitral Valve. PubMed Central [Internet]. 2021 [cited January 11, 2025]; 5(5): 811–6. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8365322/
26. Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. Blood [Internet]. 2019 [cited January 11, 2025]; 133(5):415–24. Available from: https://ashpublications.org/blood/article/133/5/415/272776/Treatment-of-rare-factor-deficiencies-other-than
27. Mohsenian S, Mannuccio P, Menegatti M, Peyvandi F. Rare inherited coagulation disorders (ricd): no longer orphan and neglected. Research and Practice in Thrombosis and Haemostasis [Internet]. 2024 [cited January 11, 2025]; 8(4): 102460–0. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11253144/
28. McRae HL, Militello L, Refaai MA. Updates in Anticoagulation Therapy Monitoring. Pubmed Central [Internet]. 2021 [citado el 11 de enero del 2025]; 9(3): 262–2. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC8001784/
29. Amiral J, Amiral C, Dunois C. Optimization of Heparin Monitoring with Anti-FXa Assays and the Impact of Dextran Sulfate for Measuring All Drug Activity. Pubmed Central [Internet]. 2021 [cited January 11, 2025]; 9(6): 700–0. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8235539/
30. Perifanis V, Neokleous N, Tsakiris DA. Update on laboratory testing and hemostasis assessment in patients receiving direct oral anticoagulants (DOACs). ELSERVIER [Internet]. 2021 [cited January 11, 2025]; 5:100084–4. Available at: https://www.sciencedirect.com/science/article/pii/S2666572721000535
31. Gosselin RC, Douxfils J. Ecarin-based coagulation testing. Pubmed[Internet]. 2020 [cited 11 January 2025]; 95(7): 863–9. Available from: https://pubmed.ncbi.nlm.nih.gov/32350907/
32. Zhang H, Liu Z, Mu G, Wang Z, Zhou S, Xie Q, et al. Diagnostic performance of coagulation indices for direct oral anticoagulant concentration. ELSERVIER [Internet]. 2020 [cited January 11, 2025]; 195: 171–9. Available at: https://www.sciencedirect.com/science/article/pii/S0049384820303224
33. Betancourt M, Carmen A, Revuelta C, Rico C, Esparza, Galbe Sánchez-Ventura, José, et al. Prophylactic use of vitamin K to prevent hemorrhagic disease of the newborn. Scielo [Internet]. 2021 [cited December 31, 2024]; 23(90): 195–205. Available from: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1139-76322021000200016
34. Gómez P, Sosa MÁ, Yáñez LA, González JJ, Majluf K, Isordia I, et al. Analysis of the quality of anticoagulation with vitamin K antagonists in three clinical scenarios in Mexico. Scielo [Internet]. 2021 [cited December 31, 2024]; 157(3). Available from: https://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0016-38132021000300296
35. Sanne L.N, Bulato C, Tullemans B, Meijden P, Simioni P, Heemskerk J. Protein C or Protein S deficiency associates with paradoxically impaired platelet‐dependent thrombus and fibrin formation under flow. Research and Practice in Thrombosis and Haemostasis [Internet]. 2022 [cited January 11, 2025]; 6(2): e12678–8. Available at: https://www.rpthjournal.org/article/S2475-0379(22)01169-4/fulltext
36. Mehic D, Schramm T, Forstner B, Haslacher H, Ay C, Pabinger I, et al. Activated protein C and free protein S in patients with mild to moderate bleeding disorders. ELSERVIER [Internet]. 2024 [cited January 11, 2025]; Available at: https://www.sciencedirect.com/science/article/pii/S0049384824000185
37. Gierula M, Ahnström J. Anticoagulant protein S—New insights on interactions and functions. ScienceDirect [Internet]. 2020 [cited 11 January 2025]; 18(11): 2801–11. Available from: https://www.sciencedirect.com/science/article/pii/S1538783622037151
38. Keragala C, Medcalf R. Plasminogen: an enigmatic zymogen. The American Society of Hematology [Internet]. 2021 [cited January 11, 2025]; 137(21): 2881–2889. Available from: https://watermark.silverchair.com/bloodbld2020008951.pdf?token=
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Melanie Prohaño Bustos, Yajaira Rueda Castillo, Paola Vinueza Ramon, Elena Pérez Laborde (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
